Francesco Pignatti
Scientific Adviser for Oncology, European Medicines Agency (EMA)
Francesco Pignatti is listed as Scientific Adviser for Oncology, European Medicines Agency (EMA). Francesco spoke at ISPOR Europe 2026 in November 2026 (speaker, “ICH E22 – General Considerations for Patient Preference Studies: Are We Ready to Move from Guidance to Practice?”). Francesco is scheduled to speak at ISPOR Europe 2026 on 10 November 2026.
Compiled from published conference agendas; not yet confirmed by Francesco. Is this you? Claim this profile.
About
Francesco Pignatti, MD, MSc in biostatistics, held roles at the European Organisation for Research and Treatment of Cancer (EORTC) Data Center until 1999. Since then, he has been with the European Medicines Agency (EMA), currently serving as Scientific Adviser for Oncology, focusing on cancer drug regulation and benefit-risk analysis.
Upcoming
ISPOR Europe 2026 8 November 2026 – 11 November 2026
- Accounting for Preference Heterogeneity in Stated Choice Data: From Good-Practice Methods to Decision-Relevant Interpretation Speaker · 10 November 2026
- Inside the EMA: A Bird's-Eye View of Europe's Medicines Regulator Speaker · 10 November 2026
- Small Sample, Big Decisions: Patient Preference Data for Regulatory and Payer Uses in Rare Diseases Speaker · 11 November 2026
EORTC Summit on Clinical Cancer Research 2027 23 March 2027 – 24 March 2027
- Session 3: Strengthening the value of patient experience data for decision-making Speaker · 23 March 2027
- Session 8: Resetting priorities in Clinical Cancer Research: from EU policies to impact (part 2) Panellist · 24 March 2027